TY - JOUR
T1 - Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia
AU - Gucalp, Rasim
AU - Ritch, Paul
AU - Wiernik, Peter H.
AU - Ravi Sarma, P.
AU - Keller, Alan
AU - Richman, Stephen P.
AU - Tauer, Kurt
AU - Neidhart, James
AU - Mallette, Lawrence E.
AU - Siegel, Robert
AU - VandePol, Christine J.
PY - 1992
Y1 - 1992
N2 - Purpose: This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of Cancer-related hypercalcemie. Patients and Methods: Sixty-five male and female adult patients with Cancer and corrected calcium levels of ≥ 12.0 mg/dL after 24 hours of hydration were randomized to receive either 60 mg APD given as a single 24-hour infusion or 7.5 mg/kg EHDP given as a 2-hour infusion daily for 3 days. Results: APD normalized corrected calcium levels in 70% (21 of 30) of patients, whereas EHDP did so in 41% (14 of 34) of patients (P = .026). The mean corrected serum calcium level decreased from 14.6 to 10.5 mg/dL in the APD-treerted group and from 13.8 to 11.6 mg/dL in the EHDP-treated group within the first week of treatment. There was no difference in response to APD in patients without versus those with bone metastases (78% v 67%). Both drugs were well tolerated. Conclusion: This study demonstrated that a single 60-mg infusion of APD is safe and more effective than EHDP given at the dose of 7.5 mg/kg for 3 days in the treatment of Cancer-related hypercalcemia.
AB - Purpose: This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of Cancer-related hypercalcemie. Patients and Methods: Sixty-five male and female adult patients with Cancer and corrected calcium levels of ≥ 12.0 mg/dL after 24 hours of hydration were randomized to receive either 60 mg APD given as a single 24-hour infusion or 7.5 mg/kg EHDP given as a 2-hour infusion daily for 3 days. Results: APD normalized corrected calcium levels in 70% (21 of 30) of patients, whereas EHDP did so in 41% (14 of 34) of patients (P = .026). The mean corrected serum calcium level decreased from 14.6 to 10.5 mg/dL in the APD-treerted group and from 13.8 to 11.6 mg/dL in the EHDP-treated group within the first week of treatment. There was no difference in response to APD in patients without versus those with bone metastases (78% v 67%). Both drugs were well tolerated. Conclusion: This study demonstrated that a single 60-mg infusion of APD is safe and more effective than EHDP given at the dose of 7.5 mg/kg for 3 days in the treatment of Cancer-related hypercalcemia.
UR - http://www.scopus.com/inward/record.url?scp=0026593561&partnerID=8YFLogxK
U2 - 10.1200/JCO.1992.10.1.134
DO - 10.1200/JCO.1992.10.1.134
M3 - Article
C2 - 1727915
AN - SCOPUS:0026593561
SN - 0732-183X
VL - 10
SP - 134
EP - 142
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 1
ER -